TScan Therapeutics Inc.’s recent filing unveils that its Director BARBERICH TIMOTHY J acquired Company’s shares for reported $99564.0 on Jun 02. In the deal valued at $2.63 per share,37,880 shares were bought. As a result of this transaction, BARBERICH TIMOTHY J now holds 37,880 shares worth roughly $ 93184.8.
Then, Lynx1 Capital Management LP sold 25,400 shares, generating $63,952 in total proceeds. Upon selling the shares at $2.52, the 10% Owner now owns 5,224,600 shares.
Before that, Silver Brian M. bought 3,158 shares. TScan Therapeutics Inc. shares valued at $4,941 were divested by the Chief Financial Officer at a price of $1.56 per share. As a result of the transaction, Silver Brian M. now holds 32,885 shares, worth roughly $80897.1.
Wedbush initiated its TScan Therapeutics Inc. [TCRX] rating to an Outperform in a research note published on Friday, June 22, 2023; the price target was $8. PT values the company’s stock at a premium of 69.25 to its Friday closing price.
Price Performance Review of TCRX
On Friday, TScan Therapeutics Inc. [NASDAQ:TCRX] saw its stock jump 3.36% to $2.46. On the same session, the stock had its day’s lowest price of $2.3391, but rose to a high of $2.57. Over the last five days, the stock has gained 10.81%. TScan Therapeutics Inc. shares have risen nearly 58.71% since the year began. Nevertheless, the stocks have fallen -12.14% over the past one year. While a 52-week high of $6.03 was reached on 05/09/23, a 52-week low of $1.45 was recorded on 01/03/23. SMA at 50 days reached $2.24, while 200 days put it at $2.37. A total of 93122.0 shares were traded, compared to the trading of 96600.0 shares in the previous session.
Levels Of Support And Resistance For TCRX Stock
The 24-hour chart illustrates a support level at 2.34, which if violated will result in even more drops to 2.23. On the upside, there is a resistance level at 2.57. A further resistance level may holdings at 2.69. The Relative Strength Index (RSI) on the 14-day chart is 62.38, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.19, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 18.33%. Stochastics %K at 68.89% indicates the stock is a holding.
How much short interest is there in TScan Therapeutics Inc.?
A steep rise in short interest was recorded in TScan Therapeutics Inc. stocks on Aug 14, 2023, dropping by 6070.0 shares to a total of 0.35 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 0.36 million shares. There was a decline of -1.72%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 0.92% of the overall stock float, the days-to-cover ratio (short ratio) fell to 4.87.
According to FactSet, TScan Therapeutics Inc.’s share price will average $10.75 in the next year, based on opinions of analysts polled by the firm. This is up nearly 362.18 percent from its previous closing price of $2.38. Analysts expect TScan Therapeutics Inc. stock to reach the higher price of $15.00, while the lowest price estimate is $6.00. However, 5 analysts have rated TCRX stock as a Buy in their predictions for 2023.